Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
- PMID: 16917004
- DOI: 10.1182/blood-2006-05-026112
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.
Similar articles
-
Pathophysiology of multiple myeloma bone disease.Hematol Oncol Clin North Am. 2007 Dec;21(6):1035-49, viii. doi: 10.1016/j.hoc.2007.08.009. Hematol Oncol Clin North Am. 2007. PMID: 17996587 Review.
-
Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.Leuk Lymphoma. 2007 Dec;48(12):2323-9. doi: 10.1080/10428190701648281. Leuk Lymphoma. 2007. PMID: 18067006 Review.
-
Pathogenesis of myeloma bone disease.J Cell Biochem. 2010 Feb 1;109(2):283-91. doi: 10.1002/jcb.22403. J Cell Biochem. 2010. PMID: 20014067
-
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104. J Bone Miner Res. 2009. PMID: 19016584
-
Mechanisms of bone destruction in multiple myeloma.Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12761. Epub 2017 Sep 21. Eur J Cancer Care (Engl). 2017. PMID: 28940410 Review.
Cited by
-
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.Blood. 2007 May 15;109(10):4470-7. doi: 10.1182/blood-2006-11-056747. Epub 2007 Jan 25. Blood. 2007. PMID: 17255354 Free PMC article.
-
Osteogenic inhibition in multiple myeloma.Cell J. 2013 Fall;15(3):266-71. Epub 2013 Aug 24. Cell J. 2013. PMID: 24027669 Free PMC article.
-
Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.PLoS One. 2015 Dec 11;10(12):e0143206. doi: 10.1371/journal.pone.0143206. eCollection 2015. PLoS One. 2015. PMID: 26659358 Free PMC article.
-
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22. Biomed Res Int. 2015. PMID: 26579531 Free PMC article. Review.
-
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.World J Stem Cells. 2014 Jul 26;6(3):322-43. doi: 10.4252/wjsc.v6.i3.322. World J Stem Cells. 2014. PMID: 25126382 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical